MH-DM-092024-Irinotecan - 1

This tender concerns the supply of Irinotecan, a crucial chemotherapeutic agent used in the treatment of various cancers, including colorectal and lung cancer. The specific formulations required are Irinotecan in solution for intravenous infusion, available in strengths of 40mg, 100mg, 300mg, and 500mg. This procurement is essential for healthcare facilities to ensure the continuity of cancer treatment protocols. Bidders are expected to provide high-quality pharmaceutical products that meet stringent regulatory standards for safety and efficacy. The tender likely involves detailed specifications regarding packaging, storage, shelf-life, and delivery timelines. Potential suppliers should demonstrate their capacity to meet the demand for these vital medications, adhering to all relevant pharmaceutical manufacturing and distribution guidelines. Further details regarding the tendering process, including submission deadlines, evaluation criteria, and contract duration, will be outlined in the full tender documentation. This procurement aims to secure a reliable supply chain for Irinotecan, supporting oncological care services.

This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals. Located in Belgium, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.